SAB BIO to Showcase Innovative Diabetes Research at EASD 2025
MIAMI, September 2025 – SAB Biotherapeutics, Inc. (NASDAQ: SABS), a pioneering biopharmaceutical company, is thrilled to announce its participation in the upcoming 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) from September 15 to 19, 2025. This prestigious annual meeting, renowned as the largest diabetes conference in the world, draws thousands of researchers, healthcare professionals, and industry leaders, facilitating discussions and showcasing groundbreaking research in diabetes treatment. SAB BIO is eager to contribute to the dialogue by presenting its innovative findings, particularly concerning SAB-142, a novel immunotherapy aimed at transforming the treatment landscape for autoimmune type 1 diabetes (T1D).
Exciting Presentation Opportunities at EASD
At EASD 2025, SAB BIO will be conducting four insightful oral presentations and hosting an INNODIA symposium. The symposium, titled "Life-Changing T1D Therapies," aims to enlighten attendees about the company’s commitment to developing disease-modifying therapies for T1D, a condition that significantly affects countless individuals around the globe.
Notable Presentations by SAB BIO
The details of the presentations are as follows:
INNODIA EASD Symposium | Life-Changing T1D Therapies Symposium
Presenter: Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer
Presentation Date & Time: Monday, September 15, 2025 | 16:40 – 20:00 CEST
Location: Lima Hall
EASD Presentations:
Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: Behind the Screens: Adventures in T1D Clinical Trials | Presentation 19
Presenter: Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer
Presentation Date & Time: Tuesday, September 16, 2025 | 10:00 – 11:30 CEST
Location: Mumbai Hall
Mechanism of Action of SAB-142 for the Treatment of Type 1 Diabetes
Session: OP 28 "Guardians of the Islet Galaxy: Protect and Replace" | Presentation 163
Presenter: Christoph Bausch, PhD, EVP and COO
Presentation Date & Time: Thursday, September 18, 2025 | 10:45 – 12:15 CEST
Location: Sofia Hall
Novel Pharmacokinetic Assay for Measuring SAB-142
Session: Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 391
Presenter: Eric Sandhurst, PhD, Director of Program Management
Presentation Date & Time: Thursday, September 18, 2025 | 14:00 – 15:00 CEST
Location: Station 03, Hall C
Specimen Quality for Multicenter Clinical Trials: Comparing Novel Blood Preservation Methods
Session: Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 392
Presenter: Eric Sandhurst, PhD, Director of Program Management
Presentation Date & Time: Thursday, September 18, 2025 | 14:00 – 15:00 CEST
Location: Station 03, Hall C
About SAB BIO
SAB BIO stands at the forefront of biopharmaceutical innovation, focusing on human, multi-specific immunoglobulins without relying on human donors. Their lead product, SAB-142, aims to redefine treatment methodologies for T1D, employing advanced genetic engineering to create a potent therapeutic that not only delays the onset of diabetes but potentially halts its progression altogether. This revolutionary approach could spark fresh hope for individuals living with T1D, as it seeks to modify the disease rather than merely manage its symptoms.
Frequently Asked Questions
What is SAB BIO's approach to treating T1D?
SAB BIO focuses on developing a novel immunotherapy called SAB-142 which aims to modify the disease course of type 1 diabetes instead of just treating symptoms.
Where and when will the EASD 2025 meeting take place?
The EASD 2025 meeting will be held from September 15 to 19, 2025, at the Vienna Congress & Convention Center in Vienna, Austria.
What type of presentations will SAB BIO deliver at EASD 2025?
SAB BIO will present four oral presentations and host a symposium focused on innovative therapies for T1D at the EASD annual meeting.
Who are the key presenters from SAB BIO?
Key presenters include Alexandra Kropotova, MD, MBA, and Christoph Bausch, PhD, who will share vital insights on SAB-142.
What sets SAB BIO apart from other biopharmaceutical companies?
SAB BIO utilizes advanced genetic engineering and Transchromosomic Bovine technology to create high-potency immunoglobulins, eliminating the need for human donors.
